

# Charlie W Lees

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/2745676/publications.pdf>

Version: 2024-02-01

68  
papers

12,337  
citations

136950

32  
h-index

128289

60  
g-index

72  
all docs

72  
docs citations

72  
times ranked

18983  
citing authors

#	ARTICLE	IF	CITATIONS
1	Host-microbe interactions have shaped the genetic architecture of inflammatory bowel disease. <i>Nature</i> , 2012, 491, 119-124.	27.8	4,038
2	Guidelines for the management of inflammatory bowel disease in adults. <i>Gut</i> , 2011, 60, 571-607.	12.1	1,127
3	Sequence variants in the autophagy gene IRGM and multiple other replicating loci contribute to Crohn's disease susceptibility. <i>Nature Genetics</i> , 2007, 39, 830-832.	21.4	1,063
4	Genome-wide association study implicates immune activation of multiple integrin genes in inflammatory bowel disease. <i>Nature Genetics</i> , 2017, 49, 256-261.	21.4	943
5	Inherited determinants of Crohn's disease and ulcerative colitis phenotypes: a genetic association study. <i>Lancet</i> , The, 2016, 387, 156-167.	13.7	607
6	Fine-mapping inflammatory bowel disease loci to single-variant resolution. <i>Nature</i> , 2017, 547, 173-178.	27.8	473
7	Predictors of anti-TNF treatment failure in anti-TNF-naive patients with active luminal Crohn's disease: a prospective, multicentre, cohort study. <i>The Lancet Gastroenterology and Hepatology</i> , 2019, 4, 341-353.	8.1	431
8	Genetic determinants of ulcerative colitis include the ECM1 locus and five loci implicated in Crohn's disease. <i>Nature Genetics</i> , 2008, 40, 710-712.	21.4	403
9	HLA-DQA1*05 Carriage Associated With Development of Anti-Drug Antibodies to Infliximab and Adalimumab in Patients With Crohn's Disease. <i>Gastroenterology</i> , 2020, 158, 189-199.	1.3	249
10	The Impact of Different DNA Extraction Kits and Laboratories upon the Assessment of Human Gut Microbiota Composition by 16S rRNA Gene Sequencing. <i>PLoS ONE</i> , 2014, 9, e88982.	2.5	236
11	Infliximab is associated with attenuated immunogenicity to BNT162b2 and ChAdOx1 nCoV-19 SARS-CoV-2 vaccines in patients with IBD. <i>Gut</i> , 2021, 70, 1884-1893.	12.1	233
12	British Society of Gastroenterology guidance for management of inflammatory bowel disease during the COVID-19 pandemic. <i>Gut</i> , 2020, 69, 984-990.	12.1	232
13	Management of Patients With Crohn's Disease and Ulcerative Colitis During the Coronavirus Disease-2019 Pandemic: Results of an International Meeting. <i>Gastroenterology</i> , 2020, 159, 6-13.e6.	1.3	185
14	HLA-DQA1 and HLA-DRB1 variants confer susceptibility to pancreatitis induced by thiopurine immunosuppressants. <i>Nature Genetics</i> , 2014, 46, 1131-1134.	21.4	165
15	Exploring the genetic architecture of inflammatory bowel disease by whole-genome sequencing identifies association at ADCY7. <i>Nature Genetics</i> , 2017, 49, 186-192.	21.4	153
16	Anti-SARS-CoV-2 antibody responses are attenuated in patients with IBD treated with infliximab. <i>Gut</i> , 2021, 70, 865-875.	12.1	153
17	IBD prevalence in Lothian, Scotland, derived by capture-recapture methodology. <i>Gut</i> , 2019, 68, 1953-1960.	12.1	134
18	Genetics of ulcerative colitis. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 831-848.	1.9	133

#	ARTICLE	IF	CITATIONS
19	Glycosylation of Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel Diseases. <i>Gastroenterology</i> , 2018, 154, 1320-1333.e10.	1.3	116
20	SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 218-224.	8.1	111
21	The Hedgehog Signalling Pathway in the Gastrointestinal Tract: Implications for Development, Homeostasis, and Disease. <i>Gastroenterology</i> , 2005, 129, 1696-1710.	1.3	100
22	COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2022, 7, 342-352.	8.1	100
23	Genetics of inflammatory bowel disease: implications for disease pathogenesis and natural history. <i>Expert Review of Gastroenterology and Hepatology</i> , 2009, 3, 513-534.	3.0	78
24	Analysis of Germline GLI1 Variation Implicates Hedgehog Signalling in the Regulation of Intestinal Inflammatory Pathways. <i>PLoS Medicine</i> , 2008, 5, e239.	8.4	63
25	Risk of severe COVID-19 outcomes associated with immune-mediated inflammatory diseases and immune-modifying therapies: a nationwide cohort study in the OpenSAFELY platform. <i>Lancet Rheumatology</i> , 2022, 4, e490-e506.	3.9	61
26	Innovation in Inflammatory Bowel Disease Care During the COVID-19 Pandemic: Results of a Global Telemedicine Survey by the International Organization for the Study of Inflammatory Bowel Disease. <i>Gastroenterology</i> , 2020, 159, 805-808.e1.	1.3	54
27	Association Between Level of Fecal Calprotectin and Progression of Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2019, 17, 2269-2276.e4.	4.4	48
28	Antibody decay, T cell immunity and breakthrough infections following two SARS-CoV-2 vaccine doses in inflammatory bowel disease patients treated with infliximab and vedolizumab. <i>Nature Communications</i> , 2022, 13, 1379.	12.8	48
29	Clinical utility and diagnostic accuracy of faecal calprotectin for IBD at first presentation to gastroenterology services in adults aged 16-50 years. <i>Journal of Crohn's and Colitis</i> , 2014, 9, 41-9.	1.3	43
30	The Impact of NOD2 Variants on Fecal Microbiota in Crohn's Disease and Controls Without Gastrointestinal Disease. <i>Inflammatory Bowel Diseases</i> , 2018, 24, 583-592.	1.9	40
31	Adalimumab and Infliximab Impair SARS-CoV-2 Antibody Responses: Results from a Therapeutic Drug Monitoring Study in 11 422 Biologic-Treated Patients. <i>Journal of Crohn's and Colitis</i> , 2022, 16, 389-397.	1.3	39
32	Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. <i>Gastroenterology</i> , 2022, 162, 1456-1475.e1.	1.3	38
33	Organisational changes and challenges for inflammatory bowel disease services in the UK during the COVID-19 pandemic. <i>Frontline Gastroenterology</i> , 2020, 11, 343-350.	1.8	37
34	Vedolizumab is effective and safe in elderly inflammatory bowel disease patients: a binational, multicenter, retrospective cohort study. <i>United European Gastroenterology Journal</i> , 2020, 8, 1076-1085.	3.8	35
35	The ACE (Albumin, CRP and Endoscopy) Index in Acute Colitis: A Simple Clinical Index on Admission that Predicts Outcome in Patients With Acute Ulcerative Colitis. <i>Inflammatory Bowel Diseases</i> , 2021, 27, 451-457.	1.9	31
36	Adaptations to the British Society of Gastroenterology guidelines on the management of acute severe UC in the context of the COVID-19 pandemic: a RAND appropriateness panel. <i>Gut</i> , 2020, 69, gutjnl-2020-321927.	12.1	28

#	ARTICLE	IF	CITATIONS
37	Normalization of Fecal Calprotectin Within 12 Months of Diagnosis Is Associated With Reduced Risk of Disease Progression in Patients With Crohn's Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021, 19, 1835-1844.e6.	4.4	26
38	Implementation of CT-P13 via a Managed Switch Programme in Crohn's Disease: 12-Month Real-World Outcomes. <i>Digestive Diseases and Sciences</i> , 2019, 64, 1660-1667.	2.3	25
39	Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 271-281.	8.1	23
40	The Impact of NOD2 Genetic Variants on the Gut Mycobiota in Crohn's Disease Patients in Remission and in Individuals Without Gastrointestinal Inflammation. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 800-812.	1.3	22
41	Cyclooxygenase-2 (COX-2) polymorphisms and risk of inflammatory bowel disease in a Scottish and Danish case-control study. <i>Inflammatory Bowel Diseases</i> , 2011, 17, 937-946.	1.9	21
42	Effectiveness and Safety of Adalimumab Biosimilar SB5 in Inflammatory Bowel Disease: Outcomes in Originator to SB5 Switch, Double Biosimilar Switch and Bio-Naïve SB5 Observational Cohorts. <i>Journal of Crohn's and Colitis</i> , 2021, 15, 2011-2021.	1.3	20
43	Higher Adalimumab Drug Levels During Maintenance Therapy for Crohn's Disease Are Associated With Biologic Remission. <i>Inflammatory Bowel Diseases</i> , 2019, 25, 1036-1043.	1.9	19
44	Real-world effectiveness and safety of ustekinumab for the treatment of Crohn's disease: the Scottish ustekinumab cohort. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021, 36, 2067-2075.	2.8	17
45	Paediatric Patients (Less Than Age of 17 Years) Account for Less Than 1.5% of All Prevalent Inflammatory Bowel Disease Cases. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2020, 71, 521-523.	1.8	15
46	Prediction of Relapse After Anti-Tumor Necrosis Factor Cessation in Crohn's Disease: Individual Participant Data Meta-analysis of 1317 Patients From 14 Studies. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 1671-1686.e16.	4.4	15
47	Associations of NOD2 polymorphisms with Erysipelotrichaceae in stool of in healthy first degree relatives of Crohn's disease subjects. <i>BMC Medical Genetics</i> , 2020, 21, 204.	2.1	11
48	COVID-19 and IBD drugs: should we change anything at the moment?. <i>Gut</i> , 2021, 70, 632-634.	12.1	11
49	Analysis of colectomy rates for ulcerative colitis in pre- and postbiological eras in Lothian, Scotland. <i>Colorectal Disease</i> , 2021, 23, 1175-1183.	1.4	10
50	Association of trough vedolizumab levels with clinical, biological and endoscopic outcomes during maintenance therapy in inflammatory bowel disease. <i>Frontline Gastroenterology</i> , 2020, 11, 117-123.	1.8	9
51	Bilateral lower limb weakness in acute severe ulcerative colitis. <i>Lancet, The</i> , 2016, 388, 101-102.	13.7	7
52	Patterns of emergency admission for IBD patients over the last 10 years in Lothian, Scotland: a retrospective prevalent cohort analysis. <i>Alimentary Pharmacology and Therapeutics</i> , 2022, 56, 67-76.	3.7	7
53	Are we addressing the top 10 research priorities in IBD?. <i>Frontline Gastroenterology</i> , 2021, 12, 564-569.	1.8	6
54	Withdrawal of the British Society of Gastroenterology IBD risk grid for COVID-19 severity. <i>Gut</i> , 2023, 72, 410-412.	12.1	5

#	ARTICLE	IF	CITATIONS
55	Mobile Health in IBD: Enhancing Care, One Phone at a Time. <i>Inflammatory Bowel Diseases</i> , 2020, 26, 163-166.	1.9	4
56	Prediction of early clinical response in patients receiving tofacitinib in the OCTAVE Induction 1 and 2 studies. <i>Therapeutic Advances in Gastroenterology</i> , 2021, 14, 175628482110547.	3.2	4
57	Early combined immunosuppression in Crohn's disease. <i>Lancet, The</i> , 2008, 371, 1995.	13.7	3
58	OWE-04...A capture-recapture study of all-age IBD point prevalence in scotland. , 2019, , .		2
59	Environmental stimuli and gut inflammation via dysbiosis in mouse and man. <i>Nature Reviews Gastroenterology and Hepatology</i> , 2020, 17, 715-716.	17.8	2
60	SARS-CoV-2 vaccination for patients with inflammatory bowel disease – Authors' reply. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 523-524.	8.1	2
61	What is the Real Impact of Corticosteroids in the Contemporary Treatment of Crohn's Disease?. <i>Clinical Gastroenterology and Hepatology</i> , 2022, 20, 468-469.	4.4	1
62	PWE-026...Endoscopy is superior to stool frequency in predicting response to steroids in acute ulcerative colitis. , 2018, , .		0
63	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2020, 18, 526.	4.4	0
64	P123...Are we addressing the top ten research priorities in management of IBD in the UK?. , 2021, , .		0
65	P109...Vedolizumab is an effective treatment for antibiotic refractory chronic pouchitis. , 2021, , .		0
66	PWE-019...Day of admission results predict outcome in acute ulcerative colitis. , 2018, , .		0
67	IBD Genomic Risk Loci and Overlap with Other Inflammatory Diseases. , 2019, , 91-115.		0
68	PMO-49...Patient perceptions about causes of flare in IBD: baseline results from the PREdiCCt study. , 2021, , .		0